Skip to main content

Creative Biolabs Unveils Revolutionary ADC Products and Services to Redefine Targeted Therapy

By: Get News
Creative Biolabs recently released updates to its cutting-edge antibody-drug conjugate (ADC) products and services, poised to revolutionize the landscape of targeted cancer therapy.

New York, USA - September 4, 2023 - With a focus on precision medicine, Creative Biolabs offers a comprehensive range of ADC solutions, providing researchers and pharmaceutical developers with powerful tools to advance cancer treatment. Recently, Creative Biolabs highlighted updates to its products and services.

Monomethyl Auristatin E ADCs: A Leap Forward in Targeted Therapy

Creative Biolabs provides a wide range of toxins and toxin derivatives that specifically target various cellular pathways and proudly introduced monomethyl auristatin E ADC cytotoxin, which belongs to the class of microtubule inhibitors and is a hot topic for the development of ADCs to target and eliminate cancer cells with superb specificity.

"Monomethyl auristatin E ADCs represent a significant milestone in the field of targeted cancer therapy," according to a scientist from Creative Biolabs. "Our expertise in ADC development enables us to offer a diverse portfolio of ADC toxins, including not only microtubule toxins but also DNA toxins and what are termed transcription toxins. These potent substances are used for the advancement of researchers' ADC development projects."

Palytoxin Prodrug ADCs: Pioneering a New Era of Targeted Treatment

With an unwavering commitment to innovation, Creative Biolabs introduced proposals to develop palytoxin prodrug ADCs, a class of antibody-enzyme conjugates utilizing the potency of palytoxin as a cytotoxic payload. Palytoxin is conjugated to an antibody, allowing for targeted delivery and activation of the prodrug that minimizes off-target effects and enhances the therapeutic window, presenting a promising avenue for safer and more effective cancer treatment.

One-Stop ADC Development Service: Empowering Breakthroughs

In addition to its diverse ADC product portfolios, Creative Biolabs offers a versatile one-stop ADC development service, catering to the specific needs of researchers and pharmaceutical companies in targeted therapy. The service encompasses every aspect of ADC development, from target selection and antibody production to linker design and payload conjugation. With its streamlined approach covering antibody production and engineering, synthetic chemistry, bioconjugation, and characterization, Creative Biolabs enables an efficient and smooth pathway to next-generation ADCs with validated target specificity and efficacy.

Key Features of Creative Biolabs' ADC Products and Services

* Unparalleled Expertise

Creative Biolabs' team of seasoned scientists brings extensive experience and expertise in ADC research and development, ensuring the highest quality products and services.

* Diverse Product Portfolio

Choose from a wide range of ADC products with different payloads, linkers, and target-specific antibodies, allowing for tailored project options.

* Cutting-Edge Technology

Leveraging state-of-the-art technology, Creative Biolabs delivers ADCs with enhanced potency, stability, and target specificity.

* Personalized Solutions

The one-stop ADC development offers customizable solutions to meet the unique requirements of each project, accelerating the path to success.

To explore Creative Biolabs' ADC products and services, please visit https://www.creative-biolabs.com/adc.

About

As a leading pioneer in biotechnology, Creative Biolabs is committed to driving the advancement of targeted cancer therapy through its innovative ADC products and services. With a vision of a future where cancer treatment is more effective and less toxic, the company aims to contribute to the global effort to conquer cancer.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/adc



Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.